Luis E. Raez\/X<\/p>\n
Luis E. Raez, Director of Thoracic Oncology Program, Chief Scientific Officer and Medical Director, and Co-Director of MCI\/FAU Florida Cancer Center of Excellence at Memorial Healthcare System, shared a post on LinkedIn<\/a>:<\/p>\n \u201cDr. Luis E. Raez \u2013 Memorial Cancer Institute, Memorial Healthcare System, Miami, USA<\/p>\n Dr. Luis Raez reviews three key genetic fusions in non-small cell lung cancer (NSCLC): NTRK, RET, and NRG1.<\/p>\n He begins with NTRK fusions, rare but highly actionable mutations found across multiple tumor types, highlighting the remarkable responses seen with TRK inhibitors like larotrectinib and entrectinib.<\/p>\n Next, he discusses RET rearrangements, found in about 1-2% of lung adenocarcinomas, emphasizing the effectiveness of selective RET inhibitors such as selpercatinib and pralsetinib.<\/p>\n Finally, Dr. Raez addresses NRG1 fusions, an emerging and less understood aberration, often seen in invasive mucinous adenocarcinomas, where HER3-targeted therapies are showing early promise in clinical trials.<\/p>\n Dr. Raez underscores the importance of comprehensive molecular profiling to detect these fusions and offer patients personalized and effective treatment options.\u201d<\/p>\n